Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations.
Berghmans T, Pasleau F, Paesmans M, Bonduelle Y, Cadranel J, Cs Toth I, Garcia C, Giner V, Holbrechts S, Lafitte JJ, Lecomte J, Louviaux I, Markiewicz E, Meert AP, Richez M, Roelandts M, Scherpereel A, Tulippe Ch, Van Houtte P, Van Schil P, Wachters C, Westeel V, Sculier JP; ELCWP. Berghmans T, et al. Among authors: richez m. Eur Respir J. 2012 Jan;39(1):9-28. doi: 10.1183/09031936.00190310. Epub 2011 Jul 7. Eur Respir J. 2012. PMID: 21737547 Free article. Review.
A phase III randomised study of concomitant induction radiochemotherapy testing two modalities of radiosensitisation by cisplatin (standard versus daily) for limited small-cell lung cancer.
Sculier JP, Lafitte JJ, Efremidis A, Florin MC, Lecomte J, Berchier MC, Richez M, Berghmans T, Scherpereel A, Meert AP, Koumakis G, Leclercq N, Paesmans M, Van Houtte P; European Lung Cancer Working Party (ELCWP). Sculier JP, et al. Among authors: richez m. Ann Oncol. 2008 Oct;19(10):1691-7. doi: 10.1093/annonc/mdn354. Epub 2008 May 25. Ann Oncol. 2008. PMID: 18504252 Free article. Clinical Trial.
Prospective Validation Obtained in a Similar Group of Patients and with Similar High Throughput Biological Tests Failed to Confirm Signatures for Prediction of Response to Chemotherapy and Survival in Advanced NSCLC: A Prospective Study from the European Lung Cancer Working Party.
Berghmans T, Ameye L, Lafitte JJ, Colinet B, Cortot A, CsToth I, Holbrechts S, Lecomte J, Mascaux C, Meert AP, Paesmans M, Richez M, Scherpereel A, Tulippe C, Willems L, Dernies T, Leclercq N, Sculier JP; European Lung Cancer Working Party. Berghmans T, et al. Among authors: richez m. Front Oncol. 2015 Jan 28;4:386. doi: 10.3389/fonc.2014.00386. eCollection 2014. Front Oncol. 2015. PMID: 25674536 Free PMC article.
Evaluation of squamous cell carcinoma antigen as a new marker for lung cancer.
Body JJ, Sculier JP, Raymakers N, Paesmans M, Ravez P, Libert P, Richez M, Dabouis G, Lacroix H, Bureau G, et al. Body JJ, et al. Among authors: richez m. Cancer. 1990 Apr 1;65(7):1552-6. doi: 10.1002/1097-0142(19900401)65:7<1552::aid-cncr2820650717>3.0.co;2-d. Cancer. 1990. PMID: 2311066
Prognostic factors for response to chemotherapy containing platinum derivatives in patients with unresectable non-small cell lung cancer. (NSCLC).
Borges M, Sculier JP, Paesmans M, Richez M, Bureau G, Dabouis G, Lecomte J, Michel J, Van Cutsem O, Schmerber J, Giner V, Berchier MC, Sergysels R, Mommen P, Klastersky J. Borges M, et al. Among authors: richez m. Lung Cancer. 1996 Dec;16(1):21-33. doi: 10.1016/s0169-5002(96)00609-5. Lung Cancer. 1996. PMID: 9017582
A phase II study testing paclitaxel as second-line single agent treatment for patients with advanced non-small cell lung cancer failing after a first-line chemotherapy.
Sculier JP, Berghmans T, Lafitte JJ, Richez M, Recloux P, Van Cutsem O, Ninane V, Mommen P, Paesmans M, Klastersky J; European Lung Cancer Working Party. Sculier JP, et al. Among authors: richez m. Lung Cancer. 2002 Jul;37(1):73-7. doi: 10.1016/s0169-5002(02)00037-5. Lung Cancer. 2002. PMID: 12057870 Clinical Trial.
A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small-cell lung cancer.
Sculier JP, Lafitte JJ, Berghmans T, Van Houtte P, Lecomte J, Thiriaux J, Efremidis A, Koumakis G, Giner V, Richez M, Corhay JL, Wackenier P, Lothaire P, Paesmans M, Mommen P, Ninane V; European Lung Cancer Working Party. Sculier JP, et al. Among authors: richez m. Ann Oncol. 2004 Mar;15(3):399-409. doi: 10.1093/annonc/mdh105. Ann Oncol. 2004. PMID: 14998841 Free article. Clinical Trial.
Survival is better predicted with a new classification of stage III unresectable non-small cell lung carcinoma treated by chemotherapy and radiotherapy.
Berghmans T, Lafitte JJ, Thiriaux J, VanHoutte P, Lecomte J, Efremidis A, Koumakis G, Giner V, Richez M, Corhay JL, Wackenier P, Lothaire P, Mommen P, Ninane V, Sculier JP; European Lung Cancer Working Party. Berghmans T, et al. Among authors: richez m. Lung Cancer. 2004 Sep;45(3):339-48. doi: 10.1016/j.lungcan.2004.02.016. Lung Cancer. 2004. PMID: 15301874
A phase III randomised study comparing concomitant radiochemotherapy as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer.
Berghmans T, Van Houtte P, Paesmans M, Giner V, Lecomte J, Koumakis G, Richez M, Holbrechts S, Roelandts M, Meert AP, Alard S, Leclercq N, Sculier JP. Berghmans T, et al. Among authors: richez m. Lung Cancer. 2009 May;64(2):187-93. doi: 10.1016/j.lungcan.2008.08.004. Epub 2008 Sep 19. Lung Cancer. 2009. PMID: 18804894 Clinical Trial.
Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study.
Scherpereel A, Berghmans T, Lafitte JJ, Colinet B, Richez M, Bonduelle Y, Meert AP, Dhalluin X, Leclercq N, Paesmans M, Willems L, Sculier JP; European Lung Cancer Working Party (ELCWP). Scherpereel A, et al. Among authors: richez m. Eur Respir J. 2011 Jan;37(1):129-35. doi: 10.1183/09031936.00037310. Epub 2010 Jun 7. Eur Respir J. 2011. PMID: 20530048 Free article. Clinical Trial.
52 results